Welcome

Sign out Have a question? We're here to help

Copyright © 2019 InvestorPlace Media, LLC. All rights reserved. 9201 Corporate Blvd, Rockville, MD 20850.

Blueprint Medicines Corp (BPMC)

$70.37 8.11 (10.33%)

19:43 EST BPMC Stock Quote Delayed 15 Minutes

Volume:

Previous Close $70.37

Market Cap 3.08B

PE Ratio -16.10

EPS -4.37

Volume (Avg. Vol.) 1.09M

Day's Range 69.77 - 77.00

52-Week Range 44.58 - 102.98

Dividend & Yield N/A (N/A)

BPMC Stock Predictions, Articles, and Blueprint Medicines Corp News

From InvestorPlace
From the Web

5 Biotech Stocks to Buy for a Strong Growth Prognosis

By Aaron Levitt, InvestorPlace Contributor Oct 25, 2019

The long term is rosy for these five biotech stocks. They have the pipelines, partners and marketed drugs to provide years of growth for investors.

Avis Budget Group Inc. (CAR) Leads 8 Notable Investor Filings

By Fintel May 4, 2017

13G and 13D filings are windows into recent activist investor activity. We look at Avis Budget Group Inc. (CAR) and 7 others

Best & Worst Performing Mid Cap Stocks for December 9, 2019

From StockNews.com Dec 9, 2019

ARQL – ARQL leads the way today as the best performing mid cap stock, closing up 103.93%.

Kinase inhibitors in focus after Merck bid for ArQule

From Seeking Alpha Dec 9, 2019

Merck's $2.7B bid for ArQule is yet another example of Big Biopharma's high regard for oral kinase inhibitors for treating cancer. ArQule's lead drug is ARQ 531, an oral inhibitor of Bruton's tyrosine

Blueprint's (BPMC) Systemic Mastocytosis Study Data Impresses

From Zacks Investment Research Dec 9, 2019

Blueprint Medicines (BPMC) posts favorable initial data from the part 1 of phase II PIONEER study on avapritinib for the treatment of patients with indolent systemic mastocytosis. Stock rises.

Analysts Offer Insights on Healthcare Companies: Springworks Therapeutics (NASDAQ: SWTX), Blueprint Medicines (NASDAQ: BPMC) and Verastem (NASDAQ: VSTM)

From Analyst Ratings Dec 9, 2019

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Springworks Therapeutics (SWTX – Research Report), Blueprint Medicines (BPMC – Research Report) and Verastem (VSTM – Research Report) with bullish sentiments. Springworks Therapeutics (SWTX) In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy

The Week Ahead In Biotech: ASH Presentations Pick Up Steam, Correvio Awaits Adcom Ruling

From Benzinga Dec 7, 2019

Biotech stocks went back and forth but managed to end the week with a gain. As usual, some stocks swung wildly in reaction to catalysts, primarily clinical readouts. Aurinia...

Best & Worst Performing Mid Cap Stocks for December 6, 2019

From StockNews.com Dec 6, 2019

FIZZ – FIZZ leads the way today as the best performing mid cap stock, closing up 12.06%.

Navellier Ratings

Powered by Portfolio Grader

Total Grade

C

Hold